Study Describing the Immunogenicity and Safety of Quadrivalent Recombinant Influenza Vaccine (RIV4) versus a licensed Quadrivalent-inactivated Influenza Vaccine (IIV4) (Fluarix® quadrivalent) in Participants 18 Years of Age and Older in South Korea

Trial Identifier: VAP00016
Sponsor: Sanofi Pasteur, a Sanofi Company
Start Date: December 2021
Primary Completion Date: September 2022
Study Completion Date: September 2022
Condition: Healthy Volunteers; Influenza Immunisation

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
South Korea Seoul, South Korea, 07441
South Korea, Gyeonggi-do Ansan-si, Gyeonggi-do, South Korea, 15355
South Korea, Seoul-teukbyeolsi Seoul, Seoul-teukbyeolsi, South Korea, 152-703